Detail akcie Edwards Lifesci online

Business Summary: Edwards Lifesciences Corporation is a global structural heart company. Its work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. TMTT category includes PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and SAPIEN M3 mitral valve replacement system. INSPIRIS RESILIA aortic valve offers RESILIA tissue and VFit technology.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Edwards Lifesciences Corp revenues increased 17% to $1.65B. Net income before extraordinary items increased 4% to $380.7M. Revenues reflect Europe segment increase of 29% to $442.6M, United States segment increase of 12% to $937.6M. Net income was partially offset by selling and general administrative other increase of 12% to $496.3M (expense).